Cue Biopharma/CUE

$2.36

11.32%
-
1D1W1MYTD1YMAX

About Cue Biopharma

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a novel class of injectable biologics designed to selectively engage and modulate tumor-specific T cells within the body to treat a broad range of cancers, chronic infectious diseases, and autoimmune diseases. The Company’s proprietary Immuno-STAT (Selective Targeting and Alteration of T Cells) platform harnesses the patient’s intrinsic immune repertoire to fully exploit its potential to fight cancer and restore health while avoiding the deleterious side effects of broad immune activation. The Company’s lead product candidate from the CUE-100 series, CUE-101, is a fusion protein biologic designed to target and activate antigen-specific T cells to fight HPV-driven cancers. Its second drug product candidate, CUE-102, targets Wilms’ Tumor 1 protein (WT-1), an oncofetal antigen. It is also developing CUE-103 and its Neo-STAT and RDI-STAT programs outside of oncology.

Ticker

CUE

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Daniel Passeri

Employees

51

Headquarters

Boston, United States

Cue Biopharma Metrics

BasicAdvanced
$90.7M
Market cap
-
P/E ratio
-$1.20
EPS
2.04
Beta
-
Dividend rate

What the Analysts think about Cue Biopharma

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 4 analysts.
334.32% upside
High $15.00
Low $8.00
$2.36
Current price
$10.25
Average price target

Cue Biopharma Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-523.8% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$2.1M
61.54%
Net income
$-11M
-16.03%
Profit margin
-523.8%
-48.02%

Cue Biopharma Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 29.93%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.38
-$0.29
-$0.29
-$0.24
-
Expected
-$0.31
-$0.29
-$0.31
-$0.34
-$0.26
Surprise
22.58%
0%
-4.92%
-29.93%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Cue Biopharma stock

Buy or sell Cue Biopharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing